<info type="DiseaseOrPhenotypicFeature">Organophosphate-induced convulsions</info> and prevention of <info type="DiseaseOrPhenotypicFeature">neuropathological damages</info>.

Such <info type="ChemicalEntity">organophosphorus</info> (OP) <info type="ChemicalEntity">compounds</info> as <info type="ChemicalEntity">diisopropylfluorophosphate</info> (<info type="ChemicalEntity">DFP</info>), <info type="ChemicalEntity">sarin</info> and <info type="ChemicalEntity">soman</info> are potent inhibitors of <info type="GeneOrGeneProduct">acetylcholinesterases</info> (<info type="GeneOrGeneProduct">AChEs</info>) and <info type="GeneOrGeneProduct">butyrylcholinesterases</info> (<info type="GeneOrGeneProduct">BChEs</info>). The acute toxicity of <info type="ChemicalEntity">OPs</info> is the result of their irreversible binding with <info type="GeneOrGeneProduct">AChEs</info> in the <info type="OrganismTaxon">central nervous system</info> (<info type="OrganismTaxon">CNS</info>), which elevates <info type="ChemicalEntity">acetylcholine</info> (<info type="ChemicalEntity">ACh</info>) levels. The protective action of subcutaneously (<info type="ChemicalEntity">SC</info>) administered <info type="ChemicalEntity">antidotes</info> or their combinations in <info type="ChemicalEntity">DFP</info> (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old <info type="OrganismTaxon">Han-Wistar male rats</info>. The rats received <info type="GeneOrGeneProduct">AChE</info> reactivator <info type="ChemicalEntity">pralidoxime-2-chloride</info> (<info type="ChemicalEntity">2PAM</info>) (30.0 mg/kg BW), anticonvulsant <info type="ChemicalEntity">diazepam</info> (2.0 mg/kg BW), <info type="GeneOrGeneProduct">A(1)-adenosine receptor</info> agonist <info type="ChemicalEntity">N(6)-cyclopentyl adenosine</info> (<info type="ChemicalEntity">CPA</info>) (2.0 mg/kg BW), <info type="ChemicalEntity">NMDA-receptor antagonist</info> <info type="ChemicalEntity">dizocilpine maleate</info> (+-<info type="ChemicalEntity">MK801 hydrogen maleate</info>) (2.0 mg/kg BW) or their combinations with <info type="ChemicalEntity">cholinolytic drug</info> <info type="ChemicalEntity">atropine sulfate</info> (50.0 mg/kg BW) immediately or 30 min after the single <info type="ChemicalEntity">SC</info> injection of <info type="ChemicalEntity">DFP</info>. The control rats received <info type="ChemicalEntity">atropine sulfate</info>, but also <info type="ChemicalEntity">saline</info> and <info type="ChemicalEntity">olive oil</info> instead of other <info type="ChemicalEntity">antidotes</info> and <info type="ChemicalEntity">DFP</info>, respectively. All rats were terminated either 24 h or 3 weeks after the <info type="ChemicalEntity">DFP</info> injection. The rats treated with <info type="ChemicalEntity">DFP-atropine</info> showed severe typical <info type="ChemicalEntity">OP-induced toxicity</info> signs. When <info type="ChemicalEntity">CPA</info>, <info type="ChemicalEntity">diazepam</info> or <info type="ChemicalEntity">2PAM</info> was given immediately after <info type="ChemicalEntity">DFP-atropine</info>, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning. <info type="ChemicalEntity">Atropine-MK801</info> did not offer any additional protection against <info type="ChemicalEntity">DFP</info> toxicity. In conclusion, <info type="ChemicalEntity">CPA</info>, <info type="ChemicalEntity">diazepam</info> and <info type="ChemicalEntity">2PAM</info> in combination with <info type="ChemicalEntity">atropine</info> prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of <info type="ChemicalEntity">DFP</info> in <info type="OrganismTaxon">rat</info>.